Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070575 | 0.80 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3KCNH2RAB9A | |
| SCHEMBL2069083 | 0.73 | NR1D1 (0.37) | RAB9AKDM4ENPC1POLBSMN1; SMN2 | |
| SCHEMBL2071322 | 0.71 | PPARA (0.41) | SLC6A4SLC6A3RAB9AKDM4ENPC1 | |
| SCHEMBL2070135 | 0.70 | FFAR1 (0.41) | SLC6A4SLC6A2SLC6A3RAB9AKDM4E | |
| SCHEMBL2069754 | 0.70 | PPARA (0.55) | KDM4E | |
| SCHEMBL84927 | 0.67 | RAB9A (0.54) | RAB9AKDM4ENPC1POLBSMN1; SMN2 | |
| SCHEMBL25883422 | 0.67 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 | |
| SCHEMBL2068822 | 0.66 | PPARA (0.58) | RAB9AKDM4ENPC1POLBSMN1; SMN2 | |
| SCHEMBL2069690 | 0.66 | MAPT (0.46) | RAB9AKDM4ENPC1POLBSMN1; SMN2 | |
| SCHEMBL11436272 | 0.65 | SLC6A2 (0.63) | SLC6A4SLC6A2SLC6A3KCNH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| CN-101014595-A | Novel cyclic aminobenzoic acid derivative | KYORIN SEIYAKU KK (JP) | 2007-08-08 | — | — | CN | disclosed |
| EP-1780210-A1 | NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | PPARA, PPARG, PPARD | SLC6A4 1813/4885SLC6A2 2893/4885SLC6A3 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.